UM1 Agreement for the Cooperative Human Tissue Network (CHTN) (Limited Competition)

Rodrigo F. Chuaqui, MD
Cancer Diagnosis Program, DCTD, NCI

BSA Meeting
March 21, 2023

The Cooperative Human Tissue Network (CHTN)



CHTN PIs: ***Board Certified; QA/QC Samples; Have contributed to Biospecimen Science; Have contributed to Biospecimen Science; Have been leaders in Biospecimen Organizations***

CHTN – a Unique Biospecimen Resource

	BIOREPOSITORIES	CHTN
Procurement	Banking for future research	Prospective procurement based on a scientific question
Specimen Storage and Distribution	Stored at the repository	Distributed upon procurement
Request Process	One time application	Frequent communication between Investigator and CHTN
Range of Samples	Usually targeted sets of samples	Wide range (tumor, normal, matched controls, rare samples)
Data Associated with Specimens	Variable, may include clinical data	Pathology report
Sample Preservation	Mostly FFPE, limited Fresh/frozen samples	Fresh/frozen samples
Access, price, speed	Variable	Entire scientific community, low bar, low price, fast delivery
Sample Utilization	Variable	Near 100%

CHTN-Scientific Impact 2017-2021

- **1,849 Individual researchers served:**

  75% Academic Investigators (most R01s); 23% Industry; 2% NIH Intramural, DOD

- **In the last 5 years, over 175K samples distributed (2017-2021)**





- **Over 500 Publications (about 50% Impact Factor > 5) and 55 Patents (most by Industry)**

- **Challenges: Funding, incorporation of a new Division, COVID**

CHTN-Rationale for Continuing Support

- **Level of requests remains high:**
  From universities, industry, SPOREs, Cancer Centers, intramural NIH researchers

- **CHTN is a well utilized Public Specimen Resource**
  CHTN Samples have been used in a wide range of research projects and current high-throughput Technologies (Genomics, Transcriptomics, Epigenomics, Proteomics, Lipidomics, Metabolomics)

- **External Review: June 2022 (5 reviewers):**
  -Consensus on the high value for the research community (R01 Grantees)
  -The prospective collection model plays a key role in basic/early translational research
  -Support for a Limited Competition to maintain stability of the Program

- **There is no alternative to the CHTN:**
  Commercial resources cannot supply the full range of services: sample types, pricing

CHTN Funding

- UM1 Cooperative Agreement-RFA; - Up to 6 awards; Limited Competition

- Current funding level: $4.7M per year (after administrative NCI RFA cut in 2019)

Current budget breakdown:

- *$3.7 to cover the cost of procurement, preparation and distribution of samples*

- *$1M: administrative and informatics functions that support network operations (including local IT) and central coordination*

CHTN Funding (cont)

Requested funding: $6.2M per year (Total for 5 years = $31M)

Justification for the increase in funding for CHTN UM1-CA:

1) Fresh samples requests increased 33% in the last 5 years

2) Requests including chart review increased from 11 to 16.5%

3) A 3-fold increase in other more difficult to fulfill requests

4) A 2-fold increase in TMAs

5) The demands for procurement of blood have increased in complexity (ctDNA or CTCs, Streck tubes)

Main Goal: Continue supplying samples to the research community at large

www.cancer.gov

www.cancer.gov/espanol